(Q34805478)

4 August 2017

1 reference

title

Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward (English)

1 reference

4 August 2017

0 references

4

David Serwadda

1 reference

4 August 2017

3

Jennifer Balkus

1 reference

4 August 2017

Nancy S Padian

1

1 reference

4 August 2017

Anne Buvé

series ordinal

2

1 reference

4 August 2017

Ward Cates

series ordinal

5

1 reference

4 August 2017

language of work or name

English

0 references

publication date

5 August 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

372

1 reference

4 August 2017

issue

9638

1 reference

4 August 2017

page(s)

585-599

1 reference

National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1. Epidemiologic results

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Acquired immunodeficiency syndrome, sexually transmitted diseases, and epidemiology. Past lessons, present knowledge, and future opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The effectiveness of condoms in reducing heterosexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Changes in sexual behavior and a decline in HIV infection among young men in Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

AIDS in Africa: an epidemiologic paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

AIDS and behavioral change to reduce risk: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

One step forward, two steps back--will there ever be an AIDS vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The prospects for and pathways toward a vaccine for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

AIDS expert doubts vaccine will be found in near future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Genital ulceration as a risk factor for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The relationship between male circumcision and HIV infection in African populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

HIV prevention: the need for methods women can use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Transforming aids prevention to meet women's needs: a focus on developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Prevention of HIV infection in developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

SAVVY® (C31G) Gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Condom effectiveness in reducing heterosexual HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

An in vitro evaluation of condoms as barriers to a small virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effectiveness of condoms in preventing HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A systematic review of published evidence on intervention impact on condom use in sub-Saharan Africa and Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Comparing prevalence of condom use among 15,379 female sex workers injecting or not injecting drugs in China.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Sexual abstinence, contraception, and condom use by young African women: a secondary analysis of survey data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Sexual and reproductive behaviour among single women aged 15-24 in eight Latin American countries: a comparative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Evaluation of the virus permeability of a new condom for women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effectiveness of female and male condoms in preventing exposure to semen during vaginal intercourse: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Female condom introduction and sexually transmitted infection prevalence: results of a community intervention trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Barrier method preferences and perceptions among Zimbabwean women and their partners.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A prospective study assessing the effects of introducing the female condom in a sex worker population in Mombasa, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Short-term acceptability of the PATH Woman's Condom among couples at three sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Microbicides 2006 conference.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

HIV-1 shedding and chlamydial urethritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

How does male circumcision protect against HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Potential HIV-1 target cells in the human penis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

HIV/AIDS epidemiology, pathogenesis, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Genital ulcer disease among STD clinic attenders in Nairobi: association with HIV-1 and circumcision status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Circumcision status and risk of sexually transmitted infection in young adult males: an analysis of a longitudinal birth cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

HIV and male circumcision--a systematic review with assessment of the quality of studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male circumcision for HIV prevention: from evidence to action?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The association between circumcision status and human immunodeficiency virus infection among homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Circumcision and male-to-male sexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Risk factors for HIV infection among men who have sex with men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Cost-effectiveness of male circumcision for HIV prevention in a South African setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The potential impact of male circumcision on HIV in Sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Complications of traditional male circumcision

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The value of contraception to prevent perinatal HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Preexposure prophylaxis for HIV: unproven promise and potential pitfalls

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Biological correlates of HIV-1 heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

An HIV vaccine--evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Progress and obstacles in the development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Antibody-based HIV-1 vaccines: recent developments and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Making HIV prevention programmes work.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Retrovirus meeting. Back-to-basics push as HIV prevention struggles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Vaginal microbicides: moving ahead after an unexpected setback.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

The spread, treatment, and prevention of HIV-1: evolution of a global pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

AIDS and absolutism--the demand for perfection in prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Risk compensation: the Achilles' heel of innovations in HIV prevention?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

Behavioural strategies to reduce HIV transmission: how to make them work better

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960885-5

7 January 2021

10.1016/S0140-6736(08)60885-5

Identifiers

DOI

1 reference

4 August 2017

1 reference